79064-26-9

Usage

Uses

Used in Pharmaceutical Industry:
9-Benzyl-2,6-dichloro-9H-purine is used as an intermediate in the synthesis of various medications, particularly for anti-cancer and anti-inflammatory drugs. Its unique structure and properties contribute to the development of novel chemical entities with potential therapeutic benefits.
Used in Agrochemical Industry:
9-benzyl-2,6-dichloro-9H-purine also serves as an intermediate in the synthesis of agrochemicals, indicating its potential applications in the agricultural sector for pest control and crop protection.
Used in Research Applications:
9-Benzyl-2,6-dichloro-9H-purine is utilized as a research reagent in biochemical and pharmacological studies. Its structure allows scientists to investigate its interactions with biological systems and explore its potential uses in creating new therapeutic agents and understanding disease mechanisms.

InChI:InChI=1/C12H8Cl2N4/c13-10-9-11(17-12(14)16-10)18(7-15-9)6-8-4-2-1-3-5-8/h1-5,7H,6H2

Upstream product

• 100-39-0 benzyl bromide 
• 5451-40-1 2,6 dichloropurine 
• 100-44-7 benzyl chloride 
• 5451-40-1 2,6-dichloropurine 
• 100-51-6 benzyl alcohol 
• 108-88-3 toluene 
• 1073366-16-1 2,6-dichloropurine hydrochloride 
• 7285-11-2 chloroform methanol 
• 5451-40-1 2,6-dichloro-7H-purine 

Downstream Products

• 125802-49-5 (9-Benzyl-2-chloro-9H-purin-6-yl)-p-tolyl-amine 
• 125802-64-4 N-(9-Benzyl-2-chloro-9H-purin-6-yl)-benzene-1,3-diamine 
• 125802-51-9 N-(9-Benzyl-2-chloro-9H-purin-6-yl)-N',N'-dimethyl-benzene-1,4-diamine 
• 176515-30-3 9-benzyl-2-chloro-6-trans-(β-phenylethenyl)-9H-purine 
• 164360-01-4 9-benzyl-2-chloro-6-phenyl-9H-purine 
• 164359-99-3 9-benzyl-2-chloro-6-(α-ethoxyethenyl)-9H-purine 
• 164360-03-6 9-benzyl-2-chloro-6-methyl-9H-purine 
• 150721-86-1 9-benzyl-2-chloro-6-iodopurine 
• 84003-57-6 9-benzyl-2-chloro-9H-purine 

Relevant academic research and scientific papers

Regioselective alkylation reaction of purines under microwave irradiation

The alkylation of purines which is generally carried out after anion formation by treatment with a base and alkyl halide is complicated and in the best cases, mixtures of N-alkylated compounds are obtained. Purine derivatives can be acquired from alkylati

CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF

Purine-derived covalent probes (e.g., halo or di-halo-substituted purine based covalent probes) and related ligands are described. The compounds can be used to identify reactive nucleophilic amino acid residues, such as reactive cysteine residues, in prot

HETEROCYCLIC NITROGEN-CONTAINING PURINE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN NEUROPROTECTION

The invention relates to heterocyclic nitrogen-containing purine derivatives, their use in the medicinal applications and compositions containing these derivatives. New generation of compounds possess selective antineurodegenerative properties on neuronal cells and tissues and can be particularly used in the treatment and prophylaxis of neurodegenerative disease, particularly in the treatment and prophylaxis of Parkinson's disease.

Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl- N6-(4-morpholin-4-ylmethyl-phenyl)- 9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations

FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to standard cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3. We present novel 2,6,9-trisubstituted purine derivatives with potent FLT3 inhibitory activity. The lead compound 7d displays nanomolar activity in biochemical assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive. The MV4-11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis. Additionally, a single dose of 7d in mice with subcutaneous MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect observed after administration of the reference FLT3 inhibitor quizartinib.

C-H amination of purine derivatives via radical oxidative coupling

An oxidative coupling reaction between purines and alkyl ethers/benzyl compounds was developed to synthesize a series of N9 alkylated purine derivatives using n-Bu4NI as a catalyst and t-BuOOH as an oxidant. This protocol uses commercially available, inexpensive catalysts and oxidants and has a wide range of substrates with a simple operation.

Trisubstituted purine inhibitors of PDGFRα and their antileukemic activity in the human eosinophilic cell line EOL-1

Inhibition of protein kinases is a validated concept for pharmacological intervention in cancers. Many kinase inhibitors have been approved for clinical use, but their practical application is often limited. Here, we describe a collection of 23 novel 2,6,9-trisubstituted purine derivatives with nanomolar inhibitory activities against PDGFRα, a receptor tyrosine kinase often found constitutively activated in various tumours. The compounds demonstrated strong and selective cytotoxicity in the human eosinophilic leukemia cell line EOL-1, whereas several other cell lines were substantially less sensitive. The cytotoxicity in EOL-1, which is known to express the FIP1L1‐PDGFRA fusion gene encoding an oncogenic kinase, correlated significantly with PDGFRα inhibition. EOL-1 cells treated with the compounds also exhibited dose-dependent inhibition of PDGFRα autophosphorylation and suppression of its downstream signaling pathways with concomitant G1 phase arrest, confirming the proposed mechanism of action. Our results show that substituted purines can be used as platforms for preparing tyrosine kinase inhibitors with specific activity towards eosinophilic leukemia.

COMPOUNDS FOR TREATING CYSTIC FIBROSIS

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).

HERBICIDAL COMPOUNDS

The present invention relates to substituted heterobicyclic carboxylic acid derivatives, as well as N-oxides and agriculturally acceptable salts thereof, and their use in controlling plant growth, particularly undesirable plant growth, in crops of useful plants. The invention extends to herbicidal compositions comprising such compounds, N-oxides and/or salts as well as mixtures of the same with one or more further active ingredients and/or a safener.

BRIDGED MORPHOLINO SUBSTITUTED PURINES

The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumours and cancers as well as other disorders or conditions related to or associated with PI3K and/or mTOR kinases.

Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: Part 1

Structure-activity relationship (SAR) efforts around our initial lead compound 1 led to the identification of potent P2X7 receptor antagonists with improved pharmacokinetic profiles. These compounds were potent and selective at the P2X7 receptor in both human and rodent. Compound (entry 31) exhibited oral efficacy in the rat MIA and CCI pain models.